{"id":173,"date":"2025-04-19T10:00:00","date_gmt":"2025-04-19T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=173"},"modified":"2025-09-03T03:41:00","modified_gmt":"2025-09-03T03:41:00","slug":"china-bd-2025-velavigo-and-ollin-biosciences-enters-a-440-million-usd-license-on-igf-1r-tshr-bsabs-vbs-102","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/173.html","title":{"rendered":"[China BD 2025] VelaVigo and Ollin Biosciences Enters a 440 million USD License on IGF-1R\/TSHR BsAbs VBS-102"},"content":{"rendered":"\n<p>Announced Date: 2025-04-18 (April 18, 2025)<\/p>\n\n\n\n<p>Asset Name: VBS-102<\/p>\n\n\n\n<p>Licensor: VelaVigo Bio (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Ollin Biosciences (USA)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: BsAbs (Bispecific antibody)<\/p>\n\n\n\n<p>Asset Target: IGF-1R\/TSHR<\/p>\n\n\n\n<p>Current Stage: <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>VelaVigo has granted Ollin an exclusive license to develop, manufacture and commercialize\u00a0VBS-102, a first-in-class bispecific\u00a0antibody,\u00a0globally (excluding Greater China).<\/p>\n\n\n\n<p>VelaVigo will maintain rights for Greater China.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>VelaVigo will receive:<\/p>\n\n\n\n<p>Upfront fee and future development, regulatory, and commercial milestone payments in cash and equity, totaling up to approximately $440 million in the aggregate, <\/p>\n\n\n\n<p>as well as tiered royalties on sales in Ollin&#8217;s territory.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model<\/p>\n\n\n\n<p><a href=\"https:\/\/www.velavigo.com\/cfnews\/51EN.html\">https:\/\/www.velavigo.com\/cfnews\/51EN.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-04-18 (April 18, 2025) Asset Name: VBS-102 Licensor: VelaVigo Bio (China) Licensee (Buyer): Ollin &hellip; <a title=\"[China BD 2025] VelaVigo and Ollin Biosciences Enters a 440 million USD License on IGF-1R\/TSHR BsAbs VBS-102\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/173.html\"><span class=\"screen-reader-text\">[China BD 2025] VelaVigo and Ollin Biosciences Enters a 440 million USD License on IGF-1R\/TSHR BsAbs VBS-102<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-173","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=173"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/173\/revisions"}],"predecessor-version":[{"id":177,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/173\/revisions\/177"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}